Payment overview · 2025
General Payments
$2,206.82
69 reported records · 19 companies
Healthcare provider profile · identity verified
Hillary Hoppe
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · SAINT HELENA, CA · NPI 1720630049
Verified facts
What the public records show
CMS Open Payments records show Hillary Hoppe received $2,206.82 in general payments during 2025 across 69 reported records.
Sumitomo Pharma America, Inc. accounted for 49.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synthroid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $1,094.95 | 49.6% | 38 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $241.22 | 10.9% | 8 | 2025 |
| Procept Biorobotics Corporation | Unresolved — no canonical attribution shown | $154.29 | 7.0% | 2 | 2025 |
| Janssen Scientific Affairs, LLC | Unresolved — no canonical attribution shown | $145.94 | 6.6% | 1 | 2025 |
| Astellas Pharma Global Development | Unresolved — no canonical attribution shown | $131.55 | 6.0% | 1 | 2025 |
| UROGEN PHARMA, INC. | Unresolved — no canonical attribution shown | $50.17 | 2.3% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $46.60 | 2.1% | 2 | 2025 |
| Endo USA, Inc. | Unresolved — no canonical attribution shown | $43.82 | 2.0% | 2 | 2025 |
| Teleflex LLC | Unresolved — no canonical attribution shown | $39.79 | 1.8% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $39.02 | 1.8% | 2 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $34.95 | 1.6% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $31.56 | 1.4% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $29.55 | 1.3% | 1 | 2025 |
| PROGENICS PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $27.92 | 1.3% | 1 | 2025 |
| Myriad Genetic Laboratories, Inc. | Unresolved — no canonical attribution shown | $24.34 | 1.1% | 1 | 2025 |
| C. R. Bard, Inc. & Subsidiaries | Unresolved — no canonical attribution shown | $20.49 | 0.9% | 1 | 2025 |
| Agiliti Surgical, Inc. | Unresolved — no canonical attribution shown | $19.56 | 0.9% | 1 | 2025 |
| Laborie Medical Technologies Corp. | Unresolved — no canonical attribution shown | $17.30 | 0.8% | 2 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $13.80 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,206.82 | 69 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $1,094.95 | 38 | 2025 |
Source payment records
|
|||||
| ERLEADA Normalized: erleada |
Drug | Janssen Biotech, Inc., Janssen Scientific Affairs, LLC | $387.16 | 9 | 2025 |
Source payment records
|
|||||
| AQUABEAM ROBOTIC SYSTEM Normalized: aquabeam robotic system |
Device | Procept Biorobotics Corporation | $154.29 | 2 | 2025 |
Source payment records
|
|||||
| Xtandi Normalized: xtandi |
Drug | Astellas Pharma Global Development | $131.55 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $46.60 | 2 | 2025 |
Source payment records
|
|||||
| XIAFLEX Normalized: xiaflex |
Biological | Endo USA, Inc. | $43.82 | 2 | 2025 |
Source payment records
|
|||||
| BARRIGEL Normalized: barrigel |
Device | Teleflex LLC | $39.79 | 1 | 2025 |
Source payment records
|
|||||
| 1788 Normalized: 1788 |
Medical Supply | Stryker Corporation | $31.56 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $29.55 | 1 | 2025 |
Source payment records
|
|||||
| PYLARIFY Normalized: pylarify |
Drug | PROGENICS PHARMACEUTICALS, INC. | $27.92 | 1 | 2025 |
Source payment records
|
|||||
| PROLARIS Normalized: prolaris |
Device | Myriad Genetic Laboratories, Inc. | $24.34 | 1 | 2025 |
Source payment records
|
|||||
| Axonics Normalized: axonics |
Device | Boston Scientific Corporation | $23.89 | 1 | 2025 |
Source payment records
|
|||||
| Bard X-Force Balloon Dilation Catheter Normalized: bard x force balloon dilation catheter |
Device | C. R. Bard, Inc. & Subsidiaries | $20.49 | 1 | 2025 |
Source payment records
|
|||||
| Sonablate HIFU Normalized: sonablate hifu |
Device | Agiliti Surgical, Inc. | $19.56 | 1 | 2025 |
Source payment records
|
|||||
| Optilume BPH Drug Coated Balloon Catheter Normalized: optilume bph drug coated balloon catheter |
Device | Laborie Medical Technologies Corp. | $17.30 | 2 | 2025 |
Source payment records
|
|||||
| AMS 700 Normalized: ams 700 |
Device | Boston Scientific Corporation | $15.13 | 1 | 2025 |
Source payment records
|
|||||
| Enhertu Normalized: enhertu |
Drug | Daiichi Sankyo Inc. | $13.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 145 | 39 |
| Atorvastatin Calcium | Atorvastatin Calcium | 104 | 35 |
| Lisinopril | Lisinopril | 80 | 28 |
| Myrbetriq | Mirabegron | 71 | 16 |
| Losartan Potassium | Losartan Potassium | 57 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 45 | 11 |
| Trazodone Hcl | Trazodone Hcl | 44 | suppressed |
| Omeprazole | Omeprazole | 39 | 11 |
| Metoprolol Succinate | Metoprolol Succinate | 37 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 32 | suppressed |
| Metformin Hcl | Metformin Hcl | 30 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 28 | 11 |
| Pantoprazole Sodium | Pantoprazole Sodium | 28 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 26 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 21 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 20 | suppressed |
| Gabapentin | Gabapentin | 20 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Jardiance | Empagliflozin | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 16 | suppressed |
| Simvastatin | Simvastatin | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 15 | suppressed |
| Prednisone | Prednisone | 15 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Furosemide | Furosemide | 12 | suppressed |
| Meloxicam | Meloxicam | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,206.82 · 69 records | Sumitomo Pharma America, Inc. | 1788, AMS 700, AQUABEAM ROBOTIC SYSTEM, Axonics, BARRIGEL, BOTOX, Bard X-Force Balloon Dilation Catheter, ERLEADA, Enhertu, GEMTESA, JOURNAVX, Optilume BPH Drug Coated Balloon Catheter, PROLARIS, PYLARIFY, Sonablate HIFU, XIAFLEX, Xtandi | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error